490 ARSENAL WAY, WATERTOWN, MA
C4 Therapeutics Enters Underwriting Agreement for 21.9M Share Offering
Investor Presentation
C4 Therapeutics and Pfizer Collaborate on Multiple Myeloma Treatment Trial
Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Reports First Quarter 2025 Financial Results and Recent Business Highlights
Annual Report to Security Holders
Changes in Board, Management or Compensation
Q2
Q1
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Free Writing Prospectus